Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients

Castle Biosciences announced the publication of a new study in Future Oncology further substantiating use of its DecisionDx-SCC test in guiding patient selection and decision-making related to the use of ART in patients with high-risk SCC based on the ability of the test to identify patients likely to benefit from treatment. “Some patients with high-risk SCC are eligible for adjuvant radiation therapy once their primary tumor has been removed; however, determining which patients should seek treatment is complicated and involves weighing numerous pros and cons against the risk of the patient’s cancer returning,” said Emily S. Ruiz, M.D., MPH, FAAD, lead author, board-certified dermatologist and Mohs micrographic surgeon at Brigham and Women’s Hospital in Boston, and Associate Professor of Dermatology at Harvard Medical School. “In this study, we were successful in validating, in an independent SCC patient cohort, that DecisionDx-SCC can objectively inform these challenging decisions by identifying patients for whom ART would be beneficial, as well as those who may be best served by avoiding it.”